| 1 |
Partly verified |
Full text not readStored summary read |
N01 · Efficacy comparison · Preserved-material preparationIs the selected subclaim reduced infection after open-fracture fixation?Required |
The preserved subclaim is reduced SSI after open-fracture fixation, originally graded D, with a note that the separate population was null at P=0.45. Parent B with 76 points and axes concern closed fractures. The selected row has no score, status or axes in the summary. |
Show the presence, scope and gaps of information in the read preserved summary; this is not completed review or a new efficacy/harms verdict |
Distinction between original selected question, subclaim grade/note and parent verdict |
Present the original records so the user can read the subclaim separately from parent context |
| 2 |
Partly verified |
Full text not readStored summary read |
N02 · Efficacy comparison · Preserved-material preparationCan the positive closed-fracture result be applied to open fractures?Required |
The preserved summary distinguishes closed and open fractures as separate prespecified populations. It records a null open-fracture result and states that the positive closed-fracture result cannot be extended. |
Show the presence, scope and gaps of information in the read preserved summary; this is not completed review or a new efficacy/harms verdict |
Materials separating populations and estimated results of the two prespecified cohorts |
Present population-specific estimates and applicability side by side |
| 3 |
Partly verified |
Full text not readStored summary read |
N03 · Efficacy comparison · Preserved-material preparationWhat is the actual denominator for the open-fracture analysis?Required |
The preserved summary gives 1,700 open-fracture patients. The evidence table’s 6,785 and 3,360/3,425 belong to closed fractures. |
Show the presence, scope and gaps of information in the read preserved summary; this is not completed review or a new efficacy/harms verdict |
Open-fracture denominators for recruitment, assignment and analysis populations |
Present clusters, people and group-specific analysis denominators separately |
| 4 |
Unverified |
Full text not readStored summary read |
N04 · Efficacy comparison · Preserved-material preparationAre open-fracture severity and anatomical scope verified?Required |
The summary identifies only the open-fracture population. The parent closed lower-extremity/pelvic-fracture label is not reused as an exact open-fracture location or severity criterion. |
Show the presence, scope and gaps of information in the read preserved summary; this is not completed review or a new efficacy/harms verdict |
Open-fracture locations, injury severity, eligibility and exclusion criteria |
Present the actual selected population and scope separately in the original report |
| 5 |
Partly verified |
Full text not readStored summary read |
N05 · Efficacy comparison · Preserved-material preparationWhat are the two alcohol preparations compared in the trial?Required |
Recorded preparations are 0.7% free iodine povacrylex with 74% isopropyl alcohol, and 2% chlorhexidine gluconate with 70% isopropyl alcohol. These identify research formulations and are not usage instructions. |
Show the presence, scope and gaps of information in the read preserved summary; this is not completed review or a new efficacy/harms verdict |
Original identities of iodine-alcohol and chlorhexidine-alcohol formulations |
Preserve formulation identities and applicability limits |
| 6 |
Partly verified |
Full text not readStored summary read |
N06 · Efficacy comparison · Preserved-material preparationCan this be extended to other antiseptics or surgeries?Required |
The parent summary specifies a comparison of two particular alcohol preparations and states that it cannot be extended to open fractures, other surgeries or aqueous iodine. |
Show the presence, scope and gaps of information in the read preserved summary; this is not completed review or a new efficacy/harms verdict |
Direct evidence matching the actual formulations and surgical context |
Express formulation- and surgery-specific results as separate questions |
| 7 |
Unverified |
Full text not readStored summary read |
N07 · Efficacy comparison · Preserved-material preparationAre concurrent antibiotics, irrigation and fixation exposures accounted for in the group comparison?Required |
The preserved material describes skin-antiseptic comparisons but no open-fracture-specific antibiotic, irrigation, fixation or other concurrent-exposure details. |
Show the presence, scope and gaps of information in the read preserved summary; this is not completed review or a new efficacy/harms verdict |
Actual surgery, antibiotics, injury care and deviation information by group |
Present concurrent exposures and deviations by group |
| 8 |
Partly verified |
Full text not readStored summary read |
N08 · Efficacy comparison · Preserved-material preparationWhat are the randomization unit and alternating-use structure?Required |
This was a cluster-randomized crossover trial in which 25 US/Canadian hospitals alternated the two preparations every two months. Assignment was at cluster-period level and is not relabeled as individual assignment. |
Show the presence, scope and gaps of information in the read preserved summary; this is not completed review or a new efficacy/harms verdict |
Design materials distinguishing hospitals, cluster-periods and individuals |
Present assignment units separately from participant units |
| 9 |
Partly verified |
Full text not readStored summary read |
N09 · Efficacy comparison · Preserved-material preparationWhat is the scope of current evidence on allocation sequence and concealment?Required |
The preserved summary quotes a Methods Centre computer-generated sequence and cluster-period allocation implementation. Parent B0 is historical verdict information; the original paper’s methods were not reviewed here. |
Show the presence, scope and gaps of information in the read preserved summary; this is not completed review or a new efficacy/harms verdict |
Allocation wording in the preserved summary actually read and original methods materials |
Present cluster-allocation implementation separately from recruitment timing |
| 10 |
Unverified |
Full text not readStored summary read |
N10 · Efficacy comparison · Preserved-material preparationWere crossover periods and temporal effects reflected in open-fracture effect estimation?Required |
The summary describes two-month alternation but no detailed period/cluster effects or crossover handling in the open-fracture model. |
Show the presence, scope and gaps of information in the read preserved summary; this is not completed review or a new efficacy/harms verdict |
Specifications of period effects, cluster correlation, crossover and analysis model |
Present period and cluster handling from the original model |
| 11 |
Partly verified |
Full text not readStored summary read |
N11 · Efficacy comparison · Preserved-material preparationWhat are the SSI definition and ascertainment times?Required |
The trial’s primary endpoint is summarized as superficial incisional infection within 30 days or deep/organ-space infection within 90 days. Symptom scores or all infections are not labeled as this same endpoint. |
Show the presence, scope and gaps of information in the read preserved summary; this is not completed review or a new efficacy/harms verdict |
Adjudication criteria and periods for superficial, deep and organ-space infection |
Present results by definition, time and infection type |
| 12 |
Partly verified |
Full text not readStored summary read |
N12 · Efficacy comparison · Preserved-material preparationAre infection-adjudication masking and surgical-team masking distinguished?Required |
The preserved summary records central adjudication unaware of assignment and infeasible surgical-team masking due to preparation characteristics. |
Show the presence, scope and gaps of information in the read preserved summary; this is not completed review or a new efficacy/harms verdict |
Masking scope for outcome adjudicators and actual surgical teams |
Distinguish masking of outcome adjudication from intervention implementation |
| 13 |
Partly verified |
Full text not readStored summary read |
N13 · Efficacy comparison · Preserved-material preparationCan the follow-up completion rate be used as an open-fracture denominator?Required |
The preserved summary gives 95% primary-analysis follow-up. It does not explicitly state that this sentence applies exclusively to open fractures. |
Show the presence, scope and gaps of information in the read preserved summary; this is not completed review or a new efficacy/harms verdict |
Open-fracture group-specific follow-up completion, missingness and withdrawal reasons |
Present actual open-fracture follow-up and missingness denominators separately |
| 14 |
Partly verified |
Full text not readStored summary read |
N14 · Efficacy comparison · Preserved-material preparationWhat are the analysis population of interest and assignment basis?Required |
The preserved analysis sentence describes eligible enrolled patients analyzed according to the antiseptic assigned to their hospital during that crossover period. |
Show the presence, scope and gaps of information in the read preserved summary; this is not completed review or a new efficacy/harms verdict |
Assignment-based analysis principles and actual inclusion/exclusion materials |
Distinguish assignment effects from effects of preparations actually received |
| 15 |
Partly verified |
Full text not readStored summary read |
N15 · Efficacy comparison · Preserved-material preparationAre infection event counts and group denominators provided for open fractures?Required |
Open-fracture results are summarized as 6.5% versus 7.3%. That summary gives no group event counts or denominators. |
Show the presence, scope and gaps of information in the read preserved summary; this is not completed review or a new efficacy/harms verdict |
Original result tables including each group’s events, denominators and analysis units |
Present actual open-fracture events together with analysis denominators |
| 16 |
Partly verified |
Full text not readStored summary read |
N16 · Efficacy comparison · Preserved-material preparationHow are the open-fracture comparison effect and confidence interval recorded?Required |
The open-fracture summary records a null result: OR 0.86, 95% CI 0.58–1.27, P=0.45. The original effect and scope are preserved. |
Show the presence, scope and gaps of information in the read preserved summary; this is not completed review or a new efficacy/harms verdict |
Effect measure, interval and P value for the selected population |
Present the original effect, interval, test and interpretation scope separately |
| 17 |
Unverified |
Full text not readStored summary read |
N17 · Efficacy comparison · Preserved-material preparationAre an open-fracture absolute risk difference and interval available?Required |
The preserved summary has open-fracture proportions and OR, but no open-fracture absolute risk difference or its interval. |
Show the presence, scope and gaps of information in the read preserved summary; this is not completed review or a new efficacy/harms verdict |
Directly reported absolute effect and uncertainty for the selected population |
If an absolute effect is reported, present the selected population’s value and interval |
| 18 |
Unverified |
Full text not readStored summary read |
N18 · Efficacy comparison · Preserved-material preparationAre open-fracture OR adjustment terms and target effect verified?Required |
The closed-fracture summary explicitly says adjusted OR; the existing open-fracture counterview records OR 0.86. |
Show the presence, scope and gaps of information in the read preserved summary; this is not completed review or a new efficacy/harms verdict |
Open-fracture adjustment model, covariates, cluster handling and effect of interest |
Present population-specific estimates’ meaning from the original report |
| 19 |
Partly verified |
Full text not readStored summary read |
N19 · Efficacy comparison · Preserved-material preparationWere the open-fracture population and registration timing distinguished prospectively?Required |
The summary records closed/open fractures as separate prespecified populations and registration in 2018 before recruitment. The registration number is NCT03523962. |
Show the presence, scope and gaps of information in the read preserved summary; this is not completed review or a new efficacy/harms verdict |
Original population distinction, registration contents and dates |
Present connections between population-specific plans and reported results |
| 20 |
Unverified |
Full text not readStored summary read |
N20 · Efficacy comparison · Preserved-material preparationAre analysis plans, multiplicity and infection-subtype hierarchy verified?Required |
The preserved summary describes the primary infection endpoint and advance population distinction. It gives no detailed within-open-fracture analysis hierarchy or multiplicity handling. |
Show the presence, scope and gaps of information in the read preserved summary; this is not completed review or a new efficacy/harms verdict |
Protocol, SAP, subtype and population-specific testing plans |
Connect the selected population’s prespecified analysis hierarchy with result tables |
| 21 |
Partly verified |
Full text not readStored summary read |
N21 · Efficacy comparison · Preserved-material preparationDo different closed/open-fracture results prove interaction?Required |
Closed-fracture results are borderline at P=0.049 and OR CI upper limit 0.999; open-fracture P=0.45. The preserved review summary distinguishes the populations. |
Show the presence, scope and gaps of information in the read preserved summary; this is not completed review or a new efficacy/harms verdict |
Population-specific effects and formal interaction or direct-comparison analyses |
Distinguish different-population results from direct tests of differences |
| 22 |
Partly verified |
Full text not readStored summary read |
N22 · Efficacy comparison · Preserved-material preparationWere the report, registration and related sheets counted as independent repeat trials?Required |
The original bibliography is one PREP-IT 2024 paper linked to NCT03523962. Related closed-fracture and selected open-fracture sheets share the parent summary. |
Show the presence, scope and gaps of information in the read preserved summary; this is not completed review or a new efficacy/harms verdict |
Population, bibliography and registration connections in the same PREPARE report |
Preserve report slots separately from trial and participant units |
| 23 |
Partly verified |
Full text not readStored summary read |
N23 · Efficacy comparison · Preserved-material preparationWhat evidence supports contrary results in other surgeries?Required |
The existing counterview mentions results favoring chlorhexidine in clean/contaminated surgeries and cesarean sections. |
Show the presence, scope and gaps of information in the read preserved summary; this is not completed review or a new efficacy/harms verdict |
Actual bibliography and populations for clean/contaminated-surgery and cesarean reports |
Present other-surgery results only as context for their own populations |
| 24 |
Partly verified |
Full text not readStored summary read |
N24 · Efficacy comparison · Preserved-material preparationAre long-term results and infection-type follow-up verified for the selected population?Required |
The preserved summary defines infection adjudication at 30/90 days and separately describes one-year reoperation in safety information. |
Show the presence, scope and gaps of information in the read preserved summary; this is not completed review or a new efficacy/harms verdict |
Open-fracture infection results by time and long-term clinical outcomes |
Present infection-adjudication times separately from long-term clinical follow-up |
| 25 |
Partly verified |
Full text not readStored summary read |
N25 · Efficacy comparison · Preserved-material preparationIs the material currently read the full original open-fracture paper?Required |
The preserved summary was actually read. The citation list contains the paper bibliography, but the evidence list’s title, population size and results are PREPARE Closed. Selected open-fracture results appear in the existing counterview. |
Show the presence, scope and gaps of information in the read preserved summary; this is not completed review or a new efficacy/harms verdict |
Access distinctions among summary copy, external abstract/full text, registration and plans |
Mark summary reading separately from unread external materials |
| 26 |
Partly verified |
Full text not readStored summary read |
N26 · Efficacy comparison · Preserved-material preparationAre public funding and manufacturer-involvement items distinguished?Required |
PCORI and CIHR supported the trial, operated by McMaster University and the University of Maryland Baltimore. The summary states that manufacturer product donations, commercial analysis, medical writing and publication funding were not reported. |
Show the presence, scope and gaps of information in the read preserved summary; this is not completed review or a new efficacy/harms verdict |
Original research-funding, product-support, outsourced-analysis, medical-writing and publication-cost disclosures |
Distinguish reported support from unknown involvement |
| 27 |
Unverified |
Full text not readStored summary read |
N27 · Efficacy comparison · Preserved-material preparationAre author affiliations, company roles and data control verified?Required |
The preserved summary describes public funding, operating institutions and nonreporting of some manufacturer support. It has no complete author-specific company-relationship or data-control items. |
Show the presence, scope and gaps of information in the read preserved summary; this is not completed review or a new efficacy/harms verdict |
Employee-author, advisory, data-access, design, analysis and publication-role disclosures |
Present public funding separately from author-specific independence |
| 28 |
Partly verified |
Full text not readStored summary read |
N28 · Supplementary harm evidenceCan one-year reoperation be used as open-fracture harms or efficacy evidence?Supplementary |
The safety summary describes similar unplanned one-year reoperation: 5.5% versus 5.9%, OR 0.96, 95% CI 0.77–1.20. |
Show the presence, scope and gaps of information in the read preserved summary; this is not completed review or a new efficacy/harms verdict |
Actual population, group-specific denominators and definition for that outcome |
Present reoperation, infection and populations separately |
| 29 |
Partly verified |
Full text not readStored summary read |
N29 · Supplementary harm evidenceWhat is the scope of unreported chemical burns and intraoperative fires?Supplementary |
The original safety sentence states that no alcohol-preparation-related chemical burns or intraoperative fires were reported in the overall trial. |
Show the presence, scope and gaps of information in the read preserved summary; this is not completed review or a new efficacy/harms verdict |
Harms collection, event definitions, exposure and population denominators |
Present harms-reporting scope together with actual observation denominators |
| 30 |
Unverified |
Full text not readStored summary read |
N30 · Supplementary harm evidenceAre long-term/rare harms and other wound-related events verified?Supplementary |
The preserved safety summary contains some reoperation and chemical-burn/fire information, but no complete open-fracture rare-harms or long-term-outcome table. |
Show the presence, scope and gaps of information in the read preserved summary; this is not completed review or a new efficacy/harms verdict |
Long-term exposure, follow-up and rare-event materials for the selected population |
Present long-term harms gaps separately from efficacy |
| 31 |
Partly verified |
Full text not readStored summary read |
N31 · Efficacy comparison · Preserved-material preparationAre Korean/English prose, axes, reference date and correction history preserved in original form?Required |
Parent Korean/English prose, axes, the 2026-08-26 reference date, empty corrections array and deliberation string, and selected subclaim are preserved in the complete existing summary. The reference date is not the current review date. |
Show the presence, scope and gaps of information in the read preserved summary; this is not completed review or a new efficacy/harms verdict |
Copies of parent Korean/English prose, axes, reference date, corrections and original subclaim |
Separate existing verdict, dates and corrections from this preparation event |
| 32 |
Partly verified |
Full text not readStored summary read |
N32 · Efficacy comparison · Preserved-material preparationAre historical candidate metadata and current preparation status separated?Required |
Only the existing subclaim unit is prepared, with parent and selected-row connections distinguished. Candidate review-pending, production-eligibility and independence markers remain historical original-selection metadata. |
Show the presence, scope and gaps of information in the read preserved summary; this is not completed review or a new efficacy/harms verdict |
Distinction between existing selection and preparation, review and independence status |
Connect original-record changes separately from preparation and existing content-review events |